Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis.
ACLD
Cirrhosis
Hepatic decompensation
Hepatic venous pressure gradient
Journal
Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
29
08
2020
accepted:
10
11
2020
pubmed:
9
12
2020
medline:
30
10
2021
entrez:
8
12
2020
Statut:
ppublish
Résumé
The liver plays a key role in the storage, metabolism and homeostasis of fat-soluble vitamins. We investigated the relation of Vitamin(Vit)A/D/E serum levels with severity of liver disease and portal hypertension (PHT). VitA/D/E serum levels were assessed in 234 patients with advanced chronic liver disease (ACLD, i.e. hepatic venous pressure gradient [HVPG] ≥ 6 mmHg). Patients with hepatocellular carcinoma, pre-/post-hepatic PHT, TIPS or liver transplantation were excluded. Most patients were male (n = 153; 65%) with a median age of 57.6 (49.7-64.5) years. Thirty-two (14%) patients had HVPG 6-9 mmHg, 66 (28%) 10-15 mmHg, and 136 (58%) ≥ 16 mmHg, respectively. VitD deficiency (25-OH-vitamin-D <50 nmol/L) was found in 133 (57%) with higher prevalence in Child-Turcotte-Pugh (CTP)-C: 85% vs. B: 66% vs. A: 47% (p < 0.001). VitD levels displayed significant but weak correlations with hepatic dysfunction and PHT. VitE levels were normal in 227 (97%) patients and displayed no relevant association with hepatic dysfunction or PHT. Only 63 (27%) patients had normal (>1.05 µmol/L) VitA levels, while 58 (25%) had mild (0.70-1.04 µmol/L), 71 (30%) moderate (0.35-0.69 µmol/L), and 42(18%) severe(<0.35 µmol/L) VitA deficiency. VitA correlated with HVPG (Rho = -0.409), CTP score (Rho = -0.646), and serum bile acid levels (Rho = -0.531; all p < 0.001). The prevalence of decompensated ACLD (dACLD) continuously increased with severity of VitA deficiency (no: 40% vs. mild: 51% vs. moderate: 67% vs. severe: 91% had dACLD; p < 0.001). CTP score (per point; OR 2.46; 95%CI 1.80-3.37; p <0.001), age (per year; OR 0.95; 95%CI 0.92-0.98; p = 0.001) and elevated bile acid levels(>10 µmol/L; OR 3.62; 95%CI 1.61-8.14; p = 0.002) were independently associated with VitA deficiency. VitA and VitD but not VitE deficiencies are highly prevalent in ACLD. VitA deficiency strongly correlates with hepatic dysfunction, PHT and bile acid levels and is associated with decompensated ACLD. NCT03267615.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The liver plays a key role in the storage, metabolism and homeostasis of fat-soluble vitamins. We investigated the relation of Vitamin(Vit)A/D/E serum levels with severity of liver disease and portal hypertension (PHT).
METHODS
METHODS
VitA/D/E serum levels were assessed in 234 patients with advanced chronic liver disease (ACLD, i.e. hepatic venous pressure gradient [HVPG] ≥ 6 mmHg). Patients with hepatocellular carcinoma, pre-/post-hepatic PHT, TIPS or liver transplantation were excluded.
RESULTS
RESULTS
Most patients were male (n = 153; 65%) with a median age of 57.6 (49.7-64.5) years. Thirty-two (14%) patients had HVPG 6-9 mmHg, 66 (28%) 10-15 mmHg, and 136 (58%) ≥ 16 mmHg, respectively. VitD deficiency (25-OH-vitamin-D <50 nmol/L) was found in 133 (57%) with higher prevalence in Child-Turcotte-Pugh (CTP)-C: 85% vs. B: 66% vs. A: 47% (p < 0.001). VitD levels displayed significant but weak correlations with hepatic dysfunction and PHT. VitE levels were normal in 227 (97%) patients and displayed no relevant association with hepatic dysfunction or PHT. Only 63 (27%) patients had normal (>1.05 µmol/L) VitA levels, while 58 (25%) had mild (0.70-1.04 µmol/L), 71 (30%) moderate (0.35-0.69 µmol/L), and 42(18%) severe(<0.35 µmol/L) VitA deficiency. VitA correlated with HVPG (Rho = -0.409), CTP score (Rho = -0.646), and serum bile acid levels (Rho = -0.531; all p < 0.001). The prevalence of decompensated ACLD (dACLD) continuously increased with severity of VitA deficiency (no: 40% vs. mild: 51% vs. moderate: 67% vs. severe: 91% had dACLD; p < 0.001). CTP score (per point; OR 2.46; 95%CI 1.80-3.37; p <0.001), age (per year; OR 0.95; 95%CI 0.92-0.98; p = 0.001) and elevated bile acid levels(>10 µmol/L; OR 3.62; 95%CI 1.61-8.14; p = 0.002) were independently associated with VitA deficiency.
CONCLUSION
CONCLUSIONS
VitA and VitD but not VitE deficiencies are highly prevalent in ACLD. VitA deficiency strongly correlates with hepatic dysfunction, PHT and bile acid levels and is associated with decompensated ACLD.
TRIAL REGISTRATION NUMBER
BACKGROUND
NCT03267615.
Identifiants
pubmed: 33289910
doi: 10.1007/s12072-020-10112-3
pii: 10.1007/s12072-020-10112-3
pmc: PMC7803875
doi:
Substances chimiques
Vitamin A
11103-57-4
Banques de données
ClinicalTrials.gov
['NCT03267615']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1093-1103Références
Di Ciaula A, et al. Bile acid physiology. Ann Hepatol 2017;16(Suppl. 1):s4–s14
doi: 10.5604/01.3001.0010.5493
Grune T, et al. β-Carotene is an important vitamin A source for humans. J Nutr 2010;140(12):2268S-2285S
doi: 10.3945/jn.109.119024
Haaker MW, Vaandrager AB, Helms JB. Retinoids in health and disease: a role for hepatic stellate cells in affecting retinoid levels. Biochim Biophys Acta 2020;1865:158674
doi: 10.1016/j.bbalip.2020.158674
Blaner WS, et al. Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim Biophys Acta 2009;1791(6):467–473
doi: 10.1016/j.bbalip.2008.11.001
Testerink N, et al. Replacement of retinyl esters by polyunsaturated triacylglycerol species in lipid droplets of hepatic stellate cells during activation. PLoS One 2012;7(4):e34945
doi: 10.1371/journal.pone.0034945
Chaves GV, et al. Association between liver vitamin A reserves and severity of nonalcoholic fatty liver disease in the class III obese following bariatric surgery. Obes Surg 2014;24(2):219–224
doi: 10.1007/s11695-013-1087-8
Peres WAF, et al. Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease. Br J Nutr 2011;106(11):1724–1731
doi: 10.1017/S0007114511002145
Kataria Y, et al. Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer. BMC Gastroenterol 2016;16:30
doi: 10.1186/s12876-016-0432-5
Chaves GV, et al. Vitamin A and retinol-binding protein deficiency among chronic liver disease patients. Nutrition 2015;31(5):664–668
doi: 10.1016/j.nut.2014.10.016
Holick MF. Vitamin D deficiency. N Engl J Med 2007;357(3):266–281
doi: 10.1056/NEJMra070553
Kubesch A, et al. Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: A prospective cohort study. PLoS One 2018;13(11):e0207162
doi: 10.1371/journal.pone.0207162
Triantos C, et al. Vitamin D-related immunomodulation in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2019;32:867–876
doi: 10.1097/MEG.0000000000001597
Yang F, et al. The value of severe vitamin D deficiency in predicting the mortality risk of patients with liver cirrhosis: a meta-analysis. Clin Res Hepatol Gastroenterol. 2019;43(6):722–729
doi: 10.1016/j.clinre.2019.03.001
Lee GY, Han SN. The role of vitamin E in immunity. Nutrients 2018;10(11):1614
doi: 10.3390/nu10111614
Hardwick RN, et al. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2010;38(12):2293–2301
doi: 10.1124/dmd.110.035006
EASL. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69(2):406–460
doi: 10.1016/j.jhep.2018.03.024
Reiberger T, et al. Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. J Vis Exp 2020. https://doi.org/10.3791/58819
doi: 10.3791/58819
pubmed: 32628153
Saeed A, et al. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2017;10(1):29
doi: 10.3390/nu10010029
Liu Y, et al. Association of serum retinoic acid with hepatic steatosis and liver injury in nonalcoholic fatty liver disease. Am J Clin Nutr 2015;102(1):130–137
doi: 10.3945/ajcn.114.105155
Ukleja A, et al. Nutritional assessment of serum and hepatic vitamin A levels in patients with cirrhosis. J Parent Enter Nutr 2002;26(3):184–188
doi: 10.1177/0148607102026003184
Kakiyama G, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013;58(5):949–955
doi: 10.1016/j.jhep.2013.01.003
Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014;11(1):55–67
doi: 10.1038/nrgastro.2013.151
Poupon RE, et al. Effect of portacaval shunt on serum bile acid concentration in patients with cirrhosis. Digestion 1977;16(1–2):138–145
doi: 10.1159/000198064
Ohkubo H, et al. Role of portal and splenic vein shunts and impaired hepatic extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology 1984;86(3):514–520
doi: 10.1016/S0016-5085(84)80022-0
de Paula TP, Ramalho A, Braulio VB. The effectiveness of relative dose response to retinol intake as an evaluation of vitamin A status of cirrhotic patients. J Hum Nutr Diet 2010;23(6):583–589
doi: 10.1111/j.1365-277X.2010.01072.x
Arantes FPW, et al. Assessment of the relative dose-response test as indicators of hepatic vitamin A stores in various stages of chronic liver disease. Nutr Clin Pract 2013;28(1):95–100
doi: 10.1177/0884533612455827
Institute of Diabetes and Digestive and Kidney Diseases. Vitamin A, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases; 2012
Pilz S, et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients 2016;8(5):278
doi: 10.3390/nu8050278
Rode A, Fourlanos S, Nicoll A. Oral vitamin D replacement is effective in chronic liver disease. Gastroenterol Clin Biol 2010;34(11):618–620
doi: 10.1016/j.gcb.2010.07.009
Yurci A, et al. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. Eur J Gastroenterol Hepatol 2011;23(12):1206–1212
doi: 10.1097/MEG.0b013e32834cd6f6
Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982;83(1 Pt 1):103–108
doi: 10.1016/S0016-5085(82)80292-8
Matloff DS, et al. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982;83(1 Pt 1):97–102
doi: 10.1016/S0016-5085(82)80291-6
Bjelakovic G, et al. Vitamin D supplementation for chronic liver diseases in adults. Cochrane Database Syst Rev 2017;11:Cd011564
pubmed: 29099543
Erhardt A, et al. Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH). Eur J Med Res 2011;16(2):76–78
doi: 10.1186/2047-783X-16-2-76
Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362(18):1675–1685
doi: 10.1056/NEJMoa0907929
Xu R, et al. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med 2015;8(3):3924–3934
pubmed: 26064294
pmcid: 4443128
Vilar-Gomez E, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology 2020;71(2):495–509
doi: 10.1002/hep.30368